Prime editing deal flurry to nail down patent rights
By Carrie Arnold,
Nature Biotechnology
| 04. 17. 2024
Tome Biosciences came out of stealth mode on 12 December with a haul of over $200 million to develop the company’s gene editing platform. Tome’s first order of business was to snap up Replace Therapeutics to expand its toolkit to one equipped to make gene edits in DNA sequences big and small.
Tome’s own genomic technology, mediated by an integrase, is well suited to large DNA up to tens of thousands of kilobases long. Replace’s CRISPR–Cas9 ligase-mediated platform, by contrast, is adept at inserting and deleting small DNA sequences of 10–100 base pairs. Having both of these technologies in its pocket, says Tome CEO Rahul Kakkar, means that the company can potentially replace an entire gene with a wild-type version rather than correct a defective version, and without requiring double-stranded breaks in DNA.
The merger, worth $65 million up front and potentially up to $185 million total for Replace, is one of the largest acquisitions in the booming prime editing field. Although Kakkar says that the acquisition was driven not by patent coverage but to expand Tome’s gene editing toolkit...
Related Articles
GeneWatch UK has prepared a briefing on the genetic modification of nature for the International Union for Conservation of Nature (IUCN) Congress in October 2025
The upcoming Congress claims to be “where the world comes together to set priorities and drive conservation and sustainable development action.” A major concern for those on the outside is that the Congress may advance plans to develop and encourage the use of synthetic biology in nature conservation. This could at first glance sound like...
By Aaron Ginn, The Washington Post | 09.12.2025
Earlier this year, I had dinner in D.C. with Jensen Huang, the president and chief executive of Nvidia. At one point, he said something that struck me: “Why is everyone here so negative?”
He wasn’t referring to the economy...
By Roni Caryn Rabin, The New York Times | 08.25.2025
Scientists have dreamed for centuries about using animal organs to treat ailing humans. In recent years, those efforts have begun to bear fruit: Researchers have begun transplanting the hearts and kidneys of genetically modified pigs into patients, with varying degrees...
The Center for Genetics and Society is delighted to recommend the current edition of GMWatch Review – Number 589. UK-based GMWatch, a long-standing ally, was founded in 1998 by Jonathan Matthews as an independent organization seeking to counter the enormous corporate political power and propaganda of the GMO industry and its supporters. Matthews and Claire Robinson are its directors and managing editors.
CGS works to ensure that social justice, equity, human rights, and democratic governance are front...